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RETINOIDS, both naturally occurring
and synthetic analogues of vitamin A,
have been shown to have several effects
experimentally that might be beneficial
in the treatment of cancer. These include
the labilization of membranes, an increase
in cell adhesiveness, an increase in hum-
oral and cell-mediated immunity, inhibi-
tion of cell growth and induction of
differentiation (Lotan, 1980). The last
effect has been demonstrated in nulli-
potent mouse embryonal carcinoma cells
(Jetten & Jetten, 1979). Differentiation
has also been noted in human teratomas
after cytotoxic chemotherapy (Hong et al.,
1977) but it is not known whether retin-
oids can induce "benign" differentiation
in human teratomas.
Cell-culture experiments have shown
growth inhibition or delay of many
types of tumours from different species
after addition of retinoids (Lotan, 1980).
However, growth inhibition in vivo has
been shown in few of the animal
tumours tested (Trown et al., 1976;
Kistler & Peter, 1979). There have been
reports ofbasal-cell carcinomas andmelan-
omas metastatic to skin responding to
high-dose topical retinoids, and there is a
report of basal-cell carcinomas responding
to oral therapy (Bollag & Ott, 1971;
Levine & Meyskens, 1980; Peck et al.,
1979). Mickshe et al. (1977) suggest that
the growth of squamous-cell carcinoma of
the lung was slowed in 9 patients by
vitamin A therapy.
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We have studied 24 patients with
various solid tumours, including 7
with metastatic teratomas, to deter-
mine whether retinoid therapy could
inhibit growth or induce differentiation of
human tumours. The synthetic aromatic
retinoid etretinate ("Tigason"; RO-9359;
ethyl all-trans-9-(4-methoxy-2,3,6-tri-
methylphenyl)-3, 7-dimethyl-2, 4, 6, 8-non-
atetraenoate), which has been found to be
useful in several dermatological conditions
(Lancet Editorial, 1981) was used in this
study.
Twenty-four patients with histologically
proven advanced neoplasms which were
refractory to conventional treatment (in-
cluding cytotoxic chemotherapy) were
entered into this study. They had measur-
able disease and had not received other
therapy within the week before the start
of this trial. Informed consent was first
obtained from the patients. Full blood
count, urea and electrolyte levels, liver
function tests and human chorionic gona-
dotrophin (hCG) and o-foetoprotein
(AFP) values where relevant were deter-
mined before the start of treatment and
regularly thereafter.
Progressive disease was defined as
enlargement of any tumour measurable
by physical examination, chest X-ray or
computerized axial tomography or tumour
marker. Static disease was defined as no
change in the size of the measurable
tumour during the study.
Treatment with etretinate was initiatedRETINOID SOLID TUMOUR TRIAL
TABLE I.-Response to etretinate in 19/24 evaluable patients
No. of Wreeks of
patients Tumour treatment
6 AMalignant teratoma 4-21
4 Ovarian carcinoma 4-21
3 Melanoma 5-70+
1 Breast carcinoma 6
1 Colon carcinoma 10
1 Adenocarcinoma Lung 5
1 Leiomyosarcoma 17
1 Hodgkin's Disease 8
1 Non-Hodgkin's Lymphoma 7
PI) Progressive (lisease for definition text
SD Static disease
at a dose of 100 mg daily in divided doses
until the patients were seen 10-14 days
later. At that visit evidence of hvper-
vitaminosis A, as demonstrated by cheil-
itis, generalized desquamation and/or fac-
ial dermatitis, was apparent in all patients.
The dose of etretinate was then reduced
to 25-50 mg daily so that the cheilitis was
maintained. Treatment continued until
there was clear evidence of tumour pro-
gression. No other therapy was given dur-
ing at least the first month of etretinate
therapy.
Twenty-four patients were entered into
the trial ofetretinate. One with metastatic
teratoma, one with non-Hodgkin's lym-
phoma, one with carcinoma of the colon
and one with myeloma died within 2
weeks of the start. A patient with ovarian
carcinoma developed intestinal obstruc-
tion 18 days after starting etretinate. These
5 patients had evidence of progressive
disease whilst receiving etretinate, but
because of the short duration of treatment
no conclusions can be drawn from them.
The results of treatment in the remaining
19 patients receiving etretinate for at
least 4 weeks are shown in Table I. Seven-
teen patients had progression of their
tumours and 2 had static disease.
The patient with adenocarcinoma of the
lung had no progression of his disease, as
FIGURE. -Contrast-enhanced CAT brain scan showing right frontal metastasis 4 months
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TABLE II.-Malignant teratomas receiving etretinate
1st Operation
hCG Histology
- Embryonal +yolk sac
+ Choriocarcinoma
- Yolk sac












+ Denotes presence and - denotes absence of serum tumour markers.
1st Operation describes histology at initial biopsy/orchidectomy.
2nd Second-look operation column shows timing of etretinate and whether differentiation was found.
shown on chest X-ray, after 5 weeks of
treatment, but he suddenly died at home
one week later.
A patient with metastatic melanoma
had a Clark Level 3 polypoidal melanoma
removed from the right calf in 1972. She
had computerized axial tomography
(CAT)-proven multiple cerebral metastases
in September, 1978, which decreased in
size after 38-25 Gy cranial irradiation and
4 courses of CCNU over the following 14
months. She has received only etretinate
since March, 1980, and CAT scan of her
brain in March 1981 showed no progression
ofher tumour (Figure 1).
Two patients with advanced ovarian
adenocarcinoma had stabilization of their
disease, as assessed by palpation and CT
scans, for 12 and 17 weeks, but there was
evidence of progression at 17 and 21
weeks respectively.
Table II gives more detail of the 6
patients with testicular teratomas. There
was X-ray evidenceoftumour enlargement
in all, and levels of either AFP, hCG or
both markers rose in 5 patients whilst
receiving etretinate. Several different
histological types of malignant teratoma
were treated, and at second-look opera-
tions after cytotoxic chemotherapy 3/6
showed evidence oftumour differentiation.
However, only one of the'3 patients show-
ing differentiation received etretinate
before surgery and he (RR) had histologi-
cal examination both before and after
etretinate. Histology of the para-aortic
mass removed after cytotoxic chemo-
therapy showed differentiated teratoma
with some embryonal elements and rhab-
domyoblasts. After 9 weeks of etretinate
treatment alone, an enlarging mediastinal
mass was removed, which showed differ-
entiated teratoma with immature cartilage
and rhabdomyoblasts.
Four patients with malignant teratoma
(2 with melanoma, one with Hodgkin's
disease and one with non-Hodgkin's lym-
phoma) received a total of 19 courses of
cytotoxic chemotherapy whilst receiving
etretinate (Table III). Marginal volume
or tumour-marker responses were seen in
3 patients with teratomas. These responses
were no greater than when the same com-
bination (VP.16-213 +actinomycin D +
cyclophosphamide; VP.16-213+cis-plat-
inum; cyclophosphamide +ci8-platinum)
had been given without etretinate, and
were of very short duration. Similarly, the
response to radiotherapy of one patient
with melanoma, one with non-Hodgkin's
lymphoma and one with teratoma whilst
receiving etretinate was no greater than
when given without. Etretinate did not
increase the toxicity of radiotherapy or
cytotoxic chemotherapy.
This study showed that in 17/19
evaluable patients, their tumours pro-
gressed whilst receiving retinoid therapy.
The aromatic retinoid etretinate was
chosen for this trial because oral admin-
istration produces signs of hypervitamin-
osis A without liver toxicity. In addition,
it has a better therapeutic ratio than other
retinoids tested in animal systems (Mayer
et al., 1978). Although in an in vitro system
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TABLE III.-Etretinate with cytotoxic chemotherapy
No. of
Other agent patients Single agent In combination Response
VP.16-213 5 7 6 3+
Cis-platinum 3 0 6 3 +
Cyclophosphamide 2 0 2 2 +
Vindesine 1 2 0 -
Vinblastine 1 1 0 -
Actinomycin D 1 0 1 -
CCNU 1 1 0 -
Estramustine 1 1 0
+ Marginal.
embryonal carcinoma cells, its main acid
metabolite was shown to be active, and
there is a high serum concentration ofthis
metabolite in vivo (Hanni et al., 1979).
Etretinate did not induce differentiation
of the malignant teratomas in the 6
evaluable patients with this tumour. There
was histological evidence of undifferentia-
ted active teratoma in one of these
patients after 9 weeks' retinoid therapy.
In the other 5 patients, in addition to
enlargement oftheir tumour masses, there
was a rise in their tumour markers whilst
on etretinate.
One of the patients in whom there was
no progression oftumour whilst on etretin-
ate had metastatica melanoma. When
melanoma metastasizes to the brain it
almost invariably runs a progressive
course. It is unlikely that this woman's
tumour was eradicated by the cranial
irradiation and CCNU, since the CT scan
has remained abnormal throughout her
treatment. Although it cannot be certain
from one case that retinoid therapy may
be beneficial in patients with metastatic
melanoma, it is worth a trial in melanoma
patients in view of its minimal toxicity
and the absence of other successful treat-
ment. The apparent temporary halt in
disease progression in 2 patients with
ovarian adenocarcinoma could be
explained by the inadequacy of methods
for monitoring this tumour.
Vitamin A was shown to enhance the
antitumour effect ofBCNU against murine
L1210 leukaemia by Cohen & Carbone
(1972) who suggested that this was
related to their combined effects on
membranes. No enhancement was shown
in the present study, even with the lipid-
soluble agents CCNU and VP.16-213.
Retinoids have many interesting proper-
ties, but this study suggests that much
more experimental work is needed before
a place can be found for them in human
cancer chemotherapy.
Since this paper was prepared similar
results have been reported in abstract
form, using 13-cis retinoic acid in advanced
cancer (Meyskens et al., 1981).
We are grateful to Roche Products Ltd, Welwyn
Garden City, Hertfordshire for the supply of etretin-
ate, to Dr E. S. Newlands for allowing us to study his
patients and to the Cancer Research Campaign for
a Research Fellowship to G. J. S. Rustin.
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